Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Corticosteroid requirements in polymyalgia rheumatica.

C M Weyand1, J W Fulbright, J M Evans

  • 1Department of Medicine, Mayo Clinic and Foundation, Rochester, Minn 55905, USA. weyand.cornelia@mayo.edu

Archives of Internal Medicine
|March 25, 1999
PubMed
Summary

Polymyalgia rheumatica (PMR) is a heterogeneous inflammatory disease. Identifying pretreatment erythrocyte sedimentation rate and interleukin 6 levels helps predict corticosteroid needs and treatment duration in PMR patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The life cycle of a T cell after vaccination - where does immune ageing strike?

Clinical and experimental immunology·2016
Same author

Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL.

Genes and immunity·2013
Same author

Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome.

Leukemia·2009
Same author

[Pathogenesis of medium- and large-vessel vasculitis].

Zeitschrift fur Rheumatologie·2009
Same author

Prominent perivascular enhancement in primary central nervous system vasculitis.

Clinical and experimental rheumatology·2008
Same author

Primary central nervous system vasculitis: comparison of patients with and without cerebral amyloid angiopathy.

Rheumatology (Oxford, England)·2008

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Polymyalgia rheumatica (PMR) is a systemic inflammatory condition affecting older adults.
  • Current corticosteroid treatment for PMR often leads to long-term adverse effects.
  • There is a need for guidelines to optimize corticosteroid use in PMR, balancing symptom relief with minimized side effects.

Purpose of the Study:

  • To identify clinical or laboratory markers for stratifying PMR patients.
  • To determine differences in corticosteroid requirements among PMR patient subsets.

Main Methods:

  • A study of 27 PMR patients treated with a standardized prednisone schedule.
  • Monthly assessments included pain scores, physician/patient evaluations, plasma interleukin 6 levels, and erythrocyte sedimentation rate.

Related Experiment Videos

  • Duration of steroid therapy and cumulative steroid dose were calculated.

    • Main Results:

    • Patients were categorized into three groups based on initial response and disease duration.
    • Low erythrocyte sedimentation rate (ESR) correlated with rapid response and shorter treatment (<1 year).
    • Elevated pretreatment pain scores and non-responsive interleukin 6 levels indicated partial response and potentially longer treatment durations.

    Conclusions:

    • Polymyalgia rheumatica exhibits heterogeneity in treatment duration and corticosteroid dosage requirements.
    • Pretreatment ESR and interleukin 6 non-responsiveness to therapy can help stratify PMR patients.
    • These parameters aid in predicting and managing individual patient treatment needs.